keyword
MENU ▼
Read by QxMD icon Read
search

lopinavir

keyword
https://www.readbyqxmd.com/read/29784846/pharmacokinetics-of-piperaquine-and-safety-profile-of-dihydroartemisinin-piperaquine-co-administered-with-antiretroviral-therapy-in-malaria-uninfected-hiv-positive-malawian-adults
#1
Clifford G Banda, Fraction Dzinjalamala, Mavuto Mukaka, Jane Mallewa, Victor Maiden, Dianne J Terlouw, David G Lalloo, Saye H Khoo, Victor Mwapasa
There are limited data on the pharmacokinetic and safety profiles of dihydroartemisinin-piperaquine (DHA-PQ) among human immunodeficiency virus infected (HIV+) individuals taking antiretroviral therapy (ART). In a two step (parallel-group) pharmacokinetic trial with intensive blood sampling, we compared area under the concentration-time curve (AUC0-28 days ) and safety outcomes of piperaquine among malaria-uninfected HIV+ adults. In step 1, half the adult dose of DHA-PQ was administered for three days as an intitial safety check in four groups (n=6/group) of HIV+ adults (age≥18 years): (i) antiretroviral-naïve, (ii) on nevirapine-based ART, (iii) on efavirenz-based ART, and (iv) on ritonavir-boosted lopinavir-based ART...
May 21, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29778008/plasma-metabolic-changes-in-chinese-hiv-infected-patients-receiving-lopinavir-ritonavir-based-treatment-implications-for-hiv-precision-therapy
#2
Xiaolin Li, Tong Wu, Yongjun Jiang, Zining Zhang, Xiaoxu Han, Wenqing Geng, Haibo Ding, Jing Kang, Qi Wang, Hong Shang
OBJECTIVES: The goal of this study is to profile the metabolic changes in the plasma of HIV patients receiving lopinavir/ritonavir (LPV/r)-based highly active antiretroviral therapy (HAART) relative to their treatment-naïve phase, aimed to identify precision therapy for HIV for improving prognosis and predicting dyslipidemia caused by LPV/r. METHODS: 38 longitudinal plasma samples were collected from 19 HIV-infected patients both before and after antiretroviral therapy, and 18 samples from healthy individuals were used as controls...
May 16, 2018: Cytokine
https://www.readbyqxmd.com/read/29772068/risk-factors-associated-with-preterm-delivery-and-low-delivery-weight-among-hiv-exposed-neonates-in-china
#3
Liming Wang, Hongxin Zhao, Weiping Cai, Jie Tao, Qingxia Zhao, Lijun Sun, Qingbo Fan, Athena P Kourtis, Colin Shepard, Fujie Zhang
OBJECTIVE: To examine the relationship between combination antiretroviral therapy (cART) and preterm delivery (PTD) or low delivery weight among pregnant Chinese women with HIV. METHODS: The present retrospective cross-sectional medical chart review enrolled pregnant women with HIV who delivered at five tertiary hospitals in China between January 1, 2009, and December 31, 2014. Generalized linear mixed modeling was used to explore PTD (<37 weeks of pregnancy) and low delivery weight (<2500 g) risk factors...
May 17, 2018: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/29760133/pharmacokinetics-and-safety-profile-of-artesunate-amodiaquine-co-administered-with-antiretroviral-therapy-in-malaria-uninfected-hiv-positive-malawian-adults
#4
Clifford G Banda, Fraction Dzinjalamala, Mavuto Mukaka, Jane Mallewa, Victor Maiden, Dianne J Terlouw, David G Lalloo, Saye H Khoo, Victor Mwapasa
There are limited data on the pharmacokinetic and safety profiles of artesunate-amodiaquine in human immnunodeficiency virus infected (HIV+) individuals receiving antiretroviral therapy. In a two-step intensive sampling pharmacokinetic trial, we compared area under the concentration-time curve from 0 to 28 days (AUC0-28 days ) of an active metabolite of amodiaquine, desethylamodiaquine, and treatment-emergent adverse events between antiretroviral therapy-naive HIV+ adults and those taking nevirapine and ritonavir-boosted lopinavir-based antiretroviral therapy...
May 14, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29747123/hiv-aspartyl-protease-inhibitors-modify-the-percentage-of-activated-leukocytes-as-well-as-serum-levels-of-il-17a-and-no-during-experimental-leishmaniasis
#5
Daniele Luísa Ribeiro Alvarenga, Amanda Helen Dos Santos Silva, Jacqueline Araújo Fiuza, Soraya Torres Gaze, Jaquelline Germano de Oliveira, Rodrigo Corrêa Oliveira, Carlos Eduardo Calzavara-Silva, Marcelo Antônio Pascoal-Xavier, Érica Alessandra Rocha Alves
HIV aspartyl protease inhibitors are able to modulate multiple defense mechanisms. However, their influence on the immune response against Leishmania has rarely been investigated. The aim of our study was to investigate whether in vivo treatment with HIV aspartyl protease inhibitors is able to modulate the immune response during Leishmania infection. Using Leishmania (L.) amazonensis-infected mice, we analyzed the disease evolution and parasite load, immunophenotypic profiles of splenic T and B lymphocytes, numbers of lymphoid aggregates in the spleen, percentages of circulating atypical lymphocytes and reactive monocytes, and serum levels of cytokines and nitric oxide (NO) after 30 days of oral treatment with lopinavir/ritonavir (LPV/RTV) or atazanavir (ATV)...
May 7, 2018: International Immunopharmacology
https://www.readbyqxmd.com/read/29746318/hiv-1-status-is-independently-associated-with-decreased-erectile-function-among-middle-aged-msm-in-the-era-of-combination-antiretroviral-therapy
#6
Maartje Dijkstra, Rik H W van Lunsen, Katherine W Kooij, Udi Davidovich, Rosan A van Zoest, Ferdinand W M N Wit, Maria Prins, Peter Reiss, Maarten F Schim van der Loeff
INTRODUCTION: HIV-1-infected MSM more often experience sexual dysfunctions than the general population. We assessed associations between HIV-1 status and decreased sexual functioning among MSM. METHODS: We used cross-sectional data from 399 HIV-1-infected MSM mostly on combination antiretroviral therapy (cART) and 366 HIV-1-uninfected MSM aged at least 45 years participating in the AGEhIV Cohort Study. The study questionnaire included questions on erectile function, sexual satisfaction, and sexual desire...
June 1, 2018: AIDS
https://www.readbyqxmd.com/read/29712434/estimating-atomic-contributions-to-hydration-and-binding-using-free-energy-perturbation
#7
Ben W J Irwin, David John Huggins
We present a general method called atom-wise free energy perturbation (AFEP), which extends a conventional molecular dynamics free energy perturbation (FEP) simulation to give the contribution to a free energy change from each atom. AFEP is derived from an expansion of the Zwanzig equation used in the exponential averaging method by defining that the system total energy can be partitioned into contributions from each atom. A partitioning method is assumed and used to group terms in the expansion to correspond to individual atoms...
April 30, 2018: Journal of Chemical Theory and Computation
https://www.readbyqxmd.com/read/29702139/renal-health-after-long-term-exposure-to-tenofovir-disoproxil-fumarate-tdf-in-hiv-hbv-positive-adults-in-ghana
#8
G Villa, R O Phillips, C Smith, A J Stockdale, A Beloukas, L T Appiah, D Chadwick, A Ruggiero, F S Sarfo, F Post, A M Geretti
OBJECTIVES: The study assessed markers of renal health in HIV/HBV co-infected patients receiving TDF-containing antiretroviral therapy in Ghana. METHODS: Urinary protein-to-creatinine ratio (uPCR) and albumin-to-protein ratio (uAPR) were measured cross-sectionally after a median of four years of TDF. At this time, alongside extensive laboratory testing, patients underwent evaluation of liver stiffness and blood pressure. The estimated glomerular filtration rate (eGFR) was measured longitudinally before and during TDF therapy...
April 24, 2018: Journal of Infection
https://www.readbyqxmd.com/read/29694825/birth-outcomes-for-pregnant-women-with-hiv-using-tenofovir-emtricitabine
#9
COMPARATIVE STUDY
Kathryn Rough, George R Seage, Paige L Williams, Sonia Hernandez-Diaz, Yanling Huo, Ellen G Chadwick, Judith S Currier, Risa M Hoffman, Emily Barr, David E Shapiro, Kunjal Patel
BACKGROUND: In a previous trial of antiretroviral therapy (ART) involving pregnant women with human immunodeficiency virus (HIV) infection, those randomly assigned to receive tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) had infants at greater risk for very premature birth and death within 14 days after delivery than those assigned to receive zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r). METHODS: Using data from two U...
April 26, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29683854/increased-cholesterol-absorption-rather-than-synthesis-is-involved-in-boosted-protease-inhibitor-associated-hypercholesterolaemia
#10
Pere Leyes, Montserrat Cofan, Ana González-Cordón, Elisa de Lazzari, Joan Trabal, Pere Domingo, Eugenia Negredo, Francesc Vidal, Maria T Forga, Jose M Gatell, Emili Ros, Esteban Martínez
OBJECTIVE: The aim of this study was to compare the differential effects of first-line efavirenz (EFV)-based vs. boosted lopinavir-based antiretroviral regimens on cholesterol metabolism. DESIGN: Multicentre, open-label, randomized clinical trial. METHODS: Forty-nine naïve HIV-infected patients were randomized (1 : 1) to receive either ritonavir-boosted lopinavir (LPV/r) or EFV both in combination with tenofovir and emtricitabine (ClinicalTrials...
April 19, 2018: AIDS
https://www.readbyqxmd.com/read/29682296/intensification-of-antiretroviral-treatment-with-raltegravir-for-pregnant-women-living-with-hiv-at-high-risk-of-vertical-transmission
#11
EDITORIAL
Thanyawee Puthanakit, Nattawan Thepnarong, Surasith Chaithongwongwatthana, Suvaporn Anugulruengkitt, Orawan Anunsittichai, Tuangtip Theerawit, Sasiwimol Ubolyam, Chitsanu Pancharoen, Praphan Phanuphak
Objectives:  The rate of vertical HIV transmission for women at high risk of HIV transmission stands at approximately 7.6%. In the present study we describe infant infection rates in women who had received raltegravir (RAL) intensification during pregnancy to a standard three-drug antiretroviral (ART) regimen in Thailand. Methods:  This prospective cohort study enrolled HIV-1-positive pregnant women at high risk of vertical transmission, as defined by (1) ART initiation at a gestational age (GA) ≥32 weeks or (2) HIV-1 RNA >1000 copies/mL at GA of 32-38 weeks while on ART...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29678735/recent-developments-of-nanotherapeutics-for-targeted-and-long-acting-combination-hiv-chemotherapy
#12
REVIEW
Yu Gao, John C Kraft, Danni Yu, Rodney J Y Ho
Combination antiretroviral therapy (cART) given orally has transformed HIV from a terminal illness to a manageable chronic disease. Yet despite the recent development of newer and more potent drugs for cART and suppression of virus in blood to undetectable levels, residual virus remains in tissues. Upon stopping cART, virus rebounds and progresses to AIDS. Current oral cART regimens have several drawbacks including (1) challenges in patient adherence due to pill fatigue or side-effects, (2) the requirement of life-long daily drug intake, and (3) limited penetration and retention in cells within lymph nodes...
April 17, 2018: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/29662875/positive-virological-outcomes-of-hiv-infected-patients-on-protease-inhibitor-based-second-line-regimen-in-cambodia-the-anrs-12276-2picam-study
#13
Olivier Ségéral, Eric Nerrienet, Sansothy Neth, Bruno Spire, Vohith Khol, Laurent Ferradini, Saramony Sarun, Chandara Mom, Sopheak Ngin, Charlotte Charpentier, Pagnaroat Men, Marion Mora, Vun Mean Chhi, Penhsun Ly, Vonthanak Saphonn
Background: Assessment of virological outcomes among HIV-infected patients receiving protease (PR) inhibitor-based second-line regimen are uncommon in Cambodia. The objective of this study is to assess the virological effectiveness of this regimen as well as impact of adherence boosting for patients experiencing virological failure. Methods: The 2PICAM study (Clinicaltrial: NCT01801618) is a cross-sectional study of HIV-infected adults on PR inhibitor-based second-line regimen since at least 6 months, conducted in 13 representative sites, comprising more than 90% of the target population...
2018: Frontiers in Public Health
https://www.readbyqxmd.com/read/29661866/reciprocal-effects-of-antiretroviral-drugs-used-to-treat-hiv-infection-on-the-fibroblast-growth-factor-21-%C3%AE-klotho-system
#14
Ricardo Moure, Pere Domingo, Joan Villarroya, Laura Gasa, José M Gallego-Escuredo, Tania Quesada-López, Samantha Morón-Ros, Alberto F Maroto, Gracia M Mateo, Joan C Domingo, Francesc Villarroya, Marta Giralt
Following antiretroviral therapy, HIV-infected patients show increased circulating levels of the antidiabetic hormone fibroblast growth factor-21 (FGF21). In contrast, expression of the FGF21-obligatory co-receptor β-Klotho (KLB) is reduced in target tissues. This situation is comparable to the FGF21 resistance status observed in obesity and type-2 diabetes. Here, we performed the first systematic study of the effects of distinct members of different antiretroviral drug classes on the FGF21/KLB system in human hepatic, adipose, and skeletal muscle cells...
April 16, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29649309/high-quality-of-life-treatment-tolerability-safety-and-efficacy-in-hiv-patients-switching-from-triple-therapy-to-lopinavir-ritonavir-monotherapy-a-randomized-clinical-trial
#15
Juan Pasquau, Carmen Hidalgo-Tenorio, María Luisa Montes, Alberto Romero-Palacios, Jorge Vergas, Isabel Sanjoaquín, José Hernández-Quero, Koldo Aguirrebengoa, Francisco Orihuela, Arkaitz Imaz, María José Ríos-Villegas, Juan Flores, María Carmen Fariñas, Pilar Vázquez, María José Galindo, Isabel García-Mercé, Fernando Lozano, Ignacio de Los Santos, Samantha Elizabeth de Jesus, Coral García-Vallecillos
TRIAL DESIGN: The QoLKAMON study evaluated quality of life, efficacy and treatment safety in HIV patients receiving lopinavir/ritonavir in monotherapy (MT) versus continuing combined antiretroviral triple treatment with a boosted protease inhibitor (TT). METHODS: This was a 24-week, open-label, multicentre study in virologically-suppressed HIV-infected participants (N = 225) with a 2:1 randomization: 146 patients who switched to MT were compared with 79 patients who remained on a TT regimen...
2018: PloS One
https://www.readbyqxmd.com/read/29649076/pharmacokinetics-of-tenofovir-alafenamide-when-co-administered-with-other-hiv-antiretrovirals
#16
Rebecca Begley, Moupali Das, Lijie Zhong, John Ling, Brian P Kearney, Joseph M Custodio
BACKGROUND: Tenofovir alafenamide (TAF), a prodrug of the nucleotide analogue tenofovir (TFV), is an antiretroviral (ARV) agent approved either as a complete regimen (elvitegravir/cobicistat/emtricitabine (F)/tenofovir alafenamide (TAF), rilpivirine/F/TAF, bictegravir/F/TAF), or for use with other ARVs (F/TAF), for treatment of HIV. TAF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. Disposition of TAF may be altered by co-medications that can inhibit or induce P-gp or BCRP transporters...
April 10, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29629852/raltegravir-versus-lopinavir-ritonavir-for-treatment-of-hiv-infected-late-presenting-pregnant-women
#17
Carlos Brites, Isabella Nóbrega, Estela Luz, Ana Gabriela Travassos, Cynthia Lorenzo, Eduardo M Netto
Background Late-presenting pregnant women pose a challenge in the prevention of HIV-1 mother-to-child-transmission. We compared the safety and efficacy of raltegravir and lopinavir/ritonavir for this population. Methods We did a single-center, pilot, open-label, randomized trial in Brazil (N = 44). We randomly allocated late-presenting HIV-infected pregnant women (older than 18 years with a plasma HIV-1 RNA >1000 copies/mL) to receive raltegravir 400 mg twice a day or lopinavir/ritonavir 400/100 mg twice a day plus zidovudine and lamivudine (1:1)...
April 9, 2018: HIV Clinical Trials
https://www.readbyqxmd.com/read/29626043/hiv-1-disease-progression-in-immune-competent-hiv-1-infected-and-breastfeeding-mothers-participating-in-the-anrs-12174-clinical-trial-in-burkina-faso-south-africa-uganda-and-zambia-a-cohort-study
#18
Eric Nagaonle Somé, Ingunn M S Engebretsen, Nicolas Nagot, Nicolas Yelbomkan Meda, Roselyne Vallo, Chipepo Kankasa, James K Tumwine, Mandisa Singata-Madliki, Kim Harper, G Justus Hofmeyr, Philippe Van de Perre, Thorkild Tylleskär
OBJECTIVE: We have assessed HIV-1 disease progression among HIV-1-positive mothers in relation to duration of any or exclusive breast feeding in the context of ANRS 12174 trial. METHODS: The analysis was completed on 203, 212, 272 and 529 HIV-1-positive and lactating mothers with CD4 count >350 cells/µL from Burkina Faso, South Africa, Uganda and Zambia, respectively. The trial compared lamivudine and lopinavir/ritonavir as a peri-exposure prophylaxis during a 50-week follow-up time...
April 5, 2018: BMJ Open
https://www.readbyqxmd.com/read/29625416/molecular-dynamics-and-ligand-docking-of-a-hinge-region-variant-of-south-african-hiv-1-subtype-c-protease
#19
Jake Zondagh, Vijayakumar Balakrishnan, Ikechukwu Achilonu, Heini W Dirr, Yasien Sayed
HIV-1 protease is an important antiretroviral drug target due to its key role in viral maturation. Computational models have been successfully used in the past to understand the dynamics of HIV-1 protease variants. We performed molecular dynamics simulations and induced fit docking on a wild-type South African HIV-1 subtype C protease and an N37T↑V hinge region variant. The simulations were initiated in a cubic cell universe and run in explicit solvent, with the wild-type and variant proteases in the fully closed conformation and under periodic boundary conditions...
March 27, 2018: Journal of Molecular Graphics & Modelling
https://www.readbyqxmd.com/read/29623447/decreased-bone-turnover-in-hiv-infected-children-on-antiretroviral-therapy
#20
Stephanie Shiau, Michael T Yin, Renate Strehlau, Faeezah Patel, Ndileka Mbete, Louise Kuhn, Ashraf Coovadia, Stephen M Arpadi
In this study, we evaluated the relationships between immune activation, bone turnover, and bone mass in virally suppressed HIV-infected children and HIV-uninfected children in South Africa. We found that decreased bone mass may occur or persist independent of immune activation and altered bone turnover. PURPOSE: HIV-infected children and adolescents have deficits in skeletal growth which include decreases in bone mass and alterations in bone microarchitecture. However, the mechanism by which HIV infection compromises bone accrual in children and adolescents is unclear...
April 5, 2018: Archives of Osteoporosis
keyword
keyword
114248
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"